Sensus Healthcare (SRTS) Q2 2025: SRT Delivery Code Set for 300% Reimbursement Surge, Pivots U.S. Outlook

August 7, 2025 | By EarningsIQ Research

U.S. reimbursement volatility defined Sensus Healthcare’s quarter, with a proposed 300 percent jump in SRT delivery code reimbursement poised to reshape outpatient economics and accelerate adoption if finalized. While regulatory uncertainty caused a pause in capital sales, international expansion and recurring revenue programs provided partial offsets. Management’s lobbying response and new distribution partnerships signal a strategic pivot to stabilize and broaden growth as the reimbursement picture clarifies into year-end.

Summary

• Reimbursement Inflection: Proposed 300 percent SRT delivery code increase could transform U.S. outpatient demand.
• International Expansion: MDSAP certification unlocks new markets as China and Asia momentum builds.
• Execution Focus: Strategic partnerships and FDA program scale-up aim to offset short-term domestic uncertainty.

Performance Analysis

Sensus Healthcare’s second quarter was marked by regulatory-driven volatility, as a proposed local coverage determination (LCD) on ultrasound reimbursement triggered a pause in domestic capital equipment sales, especially among large customers. Revenue fell year-over-year, driven primarily by lower unit sales to a key U.S. customer, though recurring revenue via FDA agreements saw growth. Gross margin compressed due to both lower sales volume and increased service costs, while operating expenses climbed across general and administrative, selling and marketing, and R&D lines as the company invested in regulatory lobbying, clinical studies, and product development. The resulting net loss and negative adjusted EBITDA reflect the cost of navigating policy headwinds and supporting pipeline readiness.

Despite these challenges, Sensus delivered 19 SRT systems in the quarter, including four to China, signaling international traction. The FDA treatment program, a recurring revenue model leveraging the Sentinel cloud platform for remote diagnostics and analytics, saw a 27 percent sequential increase in treatment volumes, highlighting operational efficiency gains and patient uptake. The company’s balance sheet remains strong, with $22.2 million in cash and no debt, providing flexibility to weather near-term turbulence and support ongoing expansion efforts.

• Regulatory Uncertainty Stalls Domestic Sales: LCD proposal on ultrasound usage led to customer pause, especially among largest accounts.
• Recurring Revenue Grows Amid Capital Slowdown: FDA program treatment volumes rose 27 percent over Q1, offsetting some capital softness.
• International Unit Growth: China shipments and MDSAP-enabled access to Brazil, Canada, Japan, and Australia provide new growth avenues.

With the proposed physician fee schedule now indicating a 300 percent increase in SRT delivery code reimbursement for outpatient settings, management expects a significant shift in U.S. demand dynamics once finalized, potentially restoring and accelerating capital sales momentum into late 2025.

Executive Commentary

Strategic Positioning

1. U.S. Reimbursement Reset

The proposed 300 percent increase in SRT delivery code reimbursement for outpatient facilities marks a potential inflection point for Sensus’s core U.S. business model. Historically, outpatient dermatology and oncology practices received just a fifth of the reimbursement compared to hospitals, limiting economic incentives for SRT adoption. The new code, if finalized, would level the playing field and unlock pent-up demand among physicians who previously hesitated to invest in SRT systems. Management’s lobbying efforts and clinical evidence submissions are central to shaping the final outcome, with clarity expected in Q4.

2. International Market Acceleration

MDSAP certification, Medical Device Single Audit Program, a regulatory pathway for multi-country access, is a strategic breakthrough. It grants Sensus immediate entry into Brazil, Canada, Japan, and Australia, as well as enhanced credibility with global partners. The company is already shipping systems to China and preparing for commercial launches in Asia and South America, with leadership traveling to Japan and Taiwan to formalize partnerships. This diversification reduces reliance on the U.S. reimbursement cycle and positions Sensus for multi-region growth.

3. Recurring Revenue and FDA Program Scale

The FDA program, a managed services model with cloud-enabled analytics and remote support (Sentinel platform), continues to scale. Treatment volume growth and improved practice efficiency highlight the value of this offering, which also supports patient awareness and onboarding. As capital sales face cyclical and regulatory headwinds, recurring revenue streams provide stability and a foundation for future growth.

4. Channel Expansion with ROS Partnership

The new relationship with Radiation Oncology Systems (ROS), a specialist distributor in hospital oncology channels, expands Sensus’s reach into hospital-based and freestanding cancer centers. ROS brings established relationships and market expertise, with management expecting tangible results before year-end. This move complements direct and outpatient channels, broadening the commercial footprint and supporting growth beyond dermatology.

5. R&D and Pipeline Readiness

Ongoing investment in next-generation platforms, with a 510K resubmission for the TDI system under FDA review, signals a commitment to innovation. Enhanced training, flexible deployment models, and expanded clinical applications are in development, positioning Sensus to capture future demand as reimbursement and market access barriers recede.

Key Considerations

This quarter’s results reflect a business in regulatory transition, balancing short-term domestic disruption with long-term strategic repositioning. Investors should weigh the following:

Key Considerations:

• Reimbursement Policy as Demand Catalyst: Final approval of the 300 percent SRT delivery code increase would dramatically improve outpatient economics and likely accelerate system installations.
• International Diversification: MDSAP certification and China momentum provide insulation from U.S. policy risk and open new revenue streams across multiple continents.
• Recurring Revenue Foundation: Growth in FDA program treatment volumes and cloud-enabled services support margin stability and customer stickiness.
• Strategic Channel Partnerships: The ROS partnership targets untapped hospital oncology markets, potentially accelerating non-dermatology segment growth.
• Pipeline Execution: Continued R&D investment and regulatory submissions are key to sustaining product leadership and expanding addressable market.

Risks

Material risks center on U.S. reimbursement outcomes, with the LCD proposal and fee schedule changes introducing both upside and downside volatility. Delays or reversals in policy decisions could prolong capital sales softness and impact cash flow. International execution depends on successful partner onboarding and regulatory navigation. Rising operating expenses and ongoing R&D investment will pressure profitability if top-line growth stalls. Competitive responses and macroeconomic shifts in healthcare capital spending remain ongoing watchpoints.

Forward Outlook

For Q3 2025, Sensus Healthcare flagged:

• Potential continued pause in U.S. capital sales until reimbursement clarity emerges
• Ongoing growth in FDA program treatment volumes and recurring revenue

For full-year 2025, management did not provide formal guidance but emphasized:

• Anticipation of a decision on the SRT delivery code reimbursement by Q4
• International expansion and ROS partnership expected to contribute to revenue in the second half

Management highlighted that resolution of reimbursement uncertainty is expected before year-end, and that a favorable outcome could trigger a surge in system placements and revenue acceleration into Q4 and 2026. International orders and recurring revenue are expected to provide partial offsets in the interim.

Takeaways

Sensus Healthcare enters the back half of 2025 at a strategic crossroads, with reimbursement policy changes set to define near-term trajectory.

• Reimbursement Policy Drives Volatility: The outcome of LCD and physician fee schedule proposals will determine the pace of U.S. adoption and capital sales recovery.
• International and Recurring Revenue Cushion: Global expansion and FDA program scale provide diversification and resilience, but cannot fully offset U.S. capital sales swings in the short term.
• Execution Watchpoints: Investors should monitor the timing of policy decisions, international partner ramp, and FDA program growth as leading indicators for revenue normalization and margin recovery.

Conclusion

Sensus Healthcare’s Q2 reflected the impact of regulatory uncertainty on its core U.S. business, but the proposed 300 percent reimbursement increase represents a potential game-changer for outpatient SRT adoption. International expansion and recurring revenue programs offer partial insulation, while strategic partnerships and pipeline execution position the company for renewed growth once the reimbursement picture clarifies.

Industry Read-Through

Sensus’s experience this quarter highlights the outsized impact of reimbursement policy on medical device adoption and capital equipment cycles, especially in outpatient and physician office settings. The shift toward equalizing reimbursement between hospitals and outpatient providers could portend broader changes across other therapeutic modalities. Companies with diversified recurring revenue streams, robust international access, and strong regulatory advocacy will be best positioned to navigate policy-driven volatility. Investors in medtech and healthcare capital equipment should monitor reimbursement trends and regulatory developments as key drivers of demand and valuation multiples across the sector.

SRTS Healthcare Medical devices Reimbursement International expansion Recurring revenue Outpatient